ArticleBMC microbiology2026
Synergistic disinfection by phage PLY101 and 1.3-dibromo-5.5-dimethylhydantoin (DBDMH) against resistant Proteus mirabilis.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Proteus mirabilis, frequently carried in the gut, is best known for causing complicated infections. With the wide application of disinfectants and lytic phages are being revisited as alternative antimicrobials, whether phage-disinfectant synergy (PDS) can improve therapeutic efficacy remains scarce. To address this gap, we isolated a novel lytic phage, designated PLY101, from wastewater. Transmission-electron microscopy and genomic analyses identified PLY101 as a double-stranded-DNA virus of the genus Novosibovirus, whose 41.513-kb genome is collinear with classical Proteus phage PM_75 (NC_027363.1). PLY101 produced clear plaques (about 3 mm) on P. mirabilis LY101 and maintained high stability across pH 5–9 and temperatures up to 55 °C. We next screened the synergy efficiency of PLY101 in combination with eight important disinfectants representing the six major biocidal classes. Time-kill assays revealed that 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) exhibited synergy with PLY101. PLY101–DBDMH pair reduced the 12-h MIC of DBDMH 3-fold. Application of PLY101 with DBDMH also triggered extensive cell damage and enlarged cell cytoskeleton. Adsorption rate showed that PDS significantly promoted the adsorption of PLY101 at 10 min, indicating that changes of bacterial morphology accelerated the absorption to receptors. In all, this study establishes PLY101 as a model phage adjuvant that reinstates DBDMH potency against P. mirabilis while cutting disinfectants use, providing a choice for low-dose, phage-enhanced disinfectants against problematic pathogens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.